Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474